Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

3.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.4K
Classification of Skeletal Muscle Relaxants01:28

Classification of Skeletal Muscle Relaxants

3.3K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
3.3K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
Centrally Acting Muscle Relaxants: Therapeutic Uses01:24

Centrally Acting Muscle Relaxants: Therapeutic Uses

1.5K
Centrally acting muscle relaxants reduce muscle tone and tension by interfering with the postsynaptic reflexes in the central nervous system.
Centrally acting drugs are classified into spasmolytic and antispasmodic drugs. Spasmolytic drugs such as baclofen, diazepam, and tizanidine inhibit spinal motor neurons and decrease muscle tone. Spasmolytic drugs are administered for severe and chronic spasms due to multiple sclerosis, cerebral palsy, stroke, and spinal cord and muscle injuries. However,...
1.5K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Spasmolytic Agents: Chemical Classification01:29

Spasmolytic Agents: Chemical Classification

1.4K
Spasmolytic agents are drugs used to alleviate muscle spasms and spasticity. They can be categorized into different chemical groups based on their mechanisms of action. Centrally acting spasmolytics primarily affect the spinal cord, while others directly target skeletal muscle cells.
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
1.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Profiling the long-term risk of severe adverse events in a cohort of multiple sclerosis patients treated with different treatment sequences: Results from the Italian Multiple Sclerosis and Related Disorders Registry (I-MS&RD) (ProSA study).

Multiple sclerosis (Houndmills, Basingstoke, England)·2026
Same author

Predictive factors of response to anti-CGRP pathway drugs in people with multiple sclerosis.

The journal of headache and pain·2026
Same author

Correction: Enhancing the endocannabinoid system to treat residual disease in relapse-free multiple sclerosis.

Frontiers in neurology·2026
Same author

Anti-NMDAR encephalitis in a patient with possible IgG4-related hypertrophic pachymeningitis: a case report.

Virchows Archiv : an international journal of pathology·2026
Same author

Enhancing the endocannabinoid system to treat residual disease in relapse-free multiple sclerosis.

Frontiers in neurology·2026
Same author

HerMeS: a registry-based evaluation of the HERCULES criteria for identifying nonrelapsing SPMS.

Journal of neurology·2026
Same journal

In conversation with Dr Harlan M. Krumholz: On preprints, the story behind medRxiv.

The Indian journal of medical research·2026
Same journal

Clay pots for reducing fluoride concentration in drinking water.

The Indian journal of medical research·2026
Same journal

Telephonic reminders for improving anti-rabies vaccination completion at a rural primary health centre: A quality improvement initiative.

The Indian journal of medical research·2026
Same journal

BMI-dependent methylation and clinical signatures in North Indian women with PCOS.

The Indian journal of medical research·2026
Same journal

Focused ultrasound-induced blood-brain barrier modulation for drug delivery in recurrent glioblastoma: A systematic review.

The Indian journal of medical research·2026
Same journal

Prevalence of metabolic dysfunction associated steatotic liver disease in type 2 diabetes mellitus in India: A systematic review and meta-analysis.

The Indian journal of medical research·2026
See all related articles

Related Experiment Video

Updated: Mar 26, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

13.0K

Multiple sclerosis--new treatment modalities.

Rocco Totaro1, Caterina Di Carmine, Carmine Marini

  • 1Multiple Sclerosis Center, Department of Neurology, San Salvatore Hospital, L'Aquila, Italy.

The Indian Journal of Medical Research
|February 3, 2016
PubMed
Summary
This summary is machine-generated.

New multiple sclerosis (MS) treatments like teriflunomide, alemtuzumab, and dimethyl fumarate offer personalized options. Careful patient selection and risk-benefit analysis are crucial for optimizing MS therapy.

More Related Videos

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

11.3K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.8K

Related Experiment Videos

Last Updated: Mar 26, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

13.0K
Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord
10:44

Two-photon Imaging of Cellular Dynamics in the Mouse Spinal Cord

Published on: February 22, 2015

11.3K
Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis
06:19

Induction and Diverse Assessment Indicators of Experimental Autoimmune Encephalomyelitis

Published on: September 9, 2022

4.8K

Area of Science:

  • Neurology
  • Immunology
  • Pharmacology

Background:

  • Multiple sclerosis (MS) treatment has evolved with new disease-modifying therapies.
  • An increasing number of drugs necessitate optimized treatment strategies for individual patients.

Purpose of the Study:

  • To review recently approved MS agents: teriflunomide, alemtuzumab, and dimethyl fumarate.
  • To focus on their mechanism of action, efficacy, safety, and tolerability.

Main Methods:

  • Literature review of recently approved multiple sclerosis therapies.
  • Analysis of experimental data on efficacy, safety, and tolerability profiles.

Main Results:

  • Teriflunomide, alemtuzumab, and dimethyl fumarate represent novel therapeutic options for MS.
  • These agents require careful risk-benefit assessment and patient selection for optimal use.

Conclusions:

  • The expanding therapeutic arsenal for MS enables personalized treatment approaches.
  • Balancing efficacy, safety, tolerability, and patient preference is key in modern MS management.